Skip to main content

What could come next for other social media firms as a jury finds Meta platforms harm children

SAN FRANCISCO (AP) — The first jury verdict in a series of social media child safety trials this year is in — and it’s not looking good for Meta. A jury in New Mexico found on Tuesday that the social media giant’s platforms are harmful to children’s mental health and imposed a $375 million penalty.

While the fine is a tiny fraction of Meta’s $201 billion revenue in 2025, the verdict illustrates a growing shift in the public’s perception of social media companies and their responsibilities in keeping young people safe on their platforms.

For years, social media companies have disputed allegations that they harm children’s mental health through deliberate design choices that addict kids to their platforms and fail to protect them from sexual predators and dangerous content. This year, several state and federal court cases are heading to trial, and while the details may vary, they all seek to hold companies responsible for what happens on their platforms.

The lawsuits have come from school districts, local, state and the federal government as well as thousands of families. The courtroom showdowns are the culmination of years of scrutiny of the platforms over child safety, and whether deliberate design choices make them addictive and serve up content that leads to depression, eating disorders or suicide.

The outcomes could challenge the companies’ First Amendment shield and Section 230 of the 1996 Communications Decency Act, which protects tech companies from liability for material posted on their platforms. They could also be costly in the form of legal fees and settlements. And they could force the companies to change how they operate, potentially losing users and advertising dollars.

Here’s a look at the major social media harms cases in the United States.

New Mexico jury fines Meta $375 million

A team led by New Mexico Attorney General Raúl Torrez, who sued Meta in 2023, built their case by posing as children on social media, then documenting sexual solicitations they received as well as Meta’s response.

Torrez wants Meta to implement more effective age verification and do more to remove bad actors from its platforms.

On Tuesday, a jury found Meta to be in violation of state consumer protection law. It found thousands of violations, each counting separately toward a penalty of $375 million.

The landmark decision came after a nearly seven-week trial. Jurors sided with state prosecutors who argued that Meta — which owns Instagram, Facebook and WhatsApp — prioritized profits over safety. The jury determined Meta violated parts of the state’s Unfair Practices Act on accusations the company hid what it knew about the dangers of child sexual exploitation on its platforms and impacts on child mental health.

The jury agreed with allegations that Meta made false or misleading statements and also agreed that Meta engaged in “unconscionable” trade practices that unfairly took advantage of the vulnerabilities of and inexperience of children.

Meta said it disagrees with the verdict and will appeal.

“We work hard to keep people safe on our platforms and are clear about the challenges of identifying and removing bad actors or harmful content. We will continue to defend ourselves vigorously, and we remain confident in our record of protecting teens online,” the company said in a statement.

The trial kicked off in early February. In his opening statement, prosecuting attorney Donald Migliori said Meta has misrepresented the safety of its platforms, choosing to engineer its algorithms to keep young people online while knowing that children are at risk of sexual exploitation.

The Los Angeles case centers on addiction

Jurors are still deliberating in a landmark social media case that seeks to hold tech companies responsible for harms to children. The plaintiff has argued the platform design features of the two remaining defendants, Meta and YouTube, were designed to be addictive, especially for young users. TikTok and Snap each settled before the trial began.

At the core of the Los Angeles case is a 20-year-old identified by the initials “KGM,” whose case could determine how thousands of similar lawsuits will play out. KGM, or Kaley, as her lawyers have called her, and a handful of other plaintiffs have been selected for bellwether trials — essentially test cases for both sides to see how their arguments play out before a jury.

“This is a monumental inflection point in social media,” said Matthew Bergman of the Seattle-based Social Media Victims Law Center, which represents more than 1,000 plaintiffs in lawsuits against social media companies. “When we started doing this four years ago, no one said we’d ever get to trial. And here we are trying our case in front of a fair and impartial jury.”

School districts head to trial

A trial scheduled for this summer pits school districts against social media companies before U.S. District Judge Yvonne Gonzalez Rogers in Oakland, California. Called a multidistrict litigation, it names six public school districts from around the country as the bellwethers.

Jayne Conroy, a lawyer on plaintiffs’ trial team, was also an attorney for plaintiffs seeking to hold pharmaceutical companies responsible for the opioid epidemic. She said the cornerstone of both cases is the same: addiction.

“With the social media case, we’re focused primarily on children and their developing brains and how addiction is such a threat to their well-being and … the harms that are caused to children — how much they’re watching and what kind of targeting is being done,” she said.

The medical science, she added, “is not really all that different, surprisingly, from an opioid or a heroin addiction. We are all talking about the dopamine reaction.”

Both the social media and the opioid cases claim negligence on the part of the defendants.

“What we were able to prove in the opioid cases is the manufacturers, the distributors, the pharmacies, they knew about the risks, they downplayed them, they oversupplied, and people died,” Conroy said. “Here, it is very much the same thing. These companies knew about the risks, they have disregarded the risks, they doubled down to get profits from advertisers over the safety of kids. And kids were harmed and kids died.”

Resolution could take years amid dueling narratives

Social media companies have disputed that their products are addictive. During questioning by the plaintiff’s lawyer during the Los Angeles trial, Zuckerberg said he still agrees with a previous statement he made that the existing body of scientific work has not proven that social media causes mental health harms.

Some researchers do indeed question whether addiction is the appropriate term to describe heavy use of social media. Social media addiction is not recognized as an official disorder in the Diagnostic and Statistical Manual of Mental Disorders, the authority within the psychiatric community.

But the companies face increasing pushback on the issue of social media’s effects on children’s mental health, not only among academics but also parents, schools and lawmakers.

“While Meta has doubled down in this area to address mounting concerns by rolling out safety features, several recent reports suggest that the company continues to aggressively prioritize teens as a user base and doesn’t always adhere to its own rules,” said Emarketer analyst Minda Smiley.

With appeals and any settlement discussions, the cases against social media companies could take years to resolve. And unlike in Europe and Australia, tech regulation in the United States is moving at a glacial pace.

When you have advanced prostate cancer: What living with the disease looks like

(CNN) — “How long do I have to live ?”When I tell a patient he has prostate cancer, this is usually what he asks me first.With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — expect a five-year relative survival rate of greater than 99% with treatment. Simply put, most men will not die from low-grade prostate cancer.However, once the cancer has spread outside the prostate to the bones and other organs the answer becomes more difficult. Treatment has changed dramatically over the past decade for advanced prostate cancer. New drugs, better imaging and the earlier use of combined therapies are helping men live longer.In a video released July 15, former President Joe Biden gave an update on his prostate cancer, saying he was receiving treatments that have been going well. In May 2025, Biden officially announced that he had an aggressive form of prostate cancer that had spread to his bones. Since then, based on official updates, he has continued hormone therapy, completed a course of radiation and maintained a public presence.His diagnosis brought renewed attention to prostate cancer screening and treatment. Now, more than a year later, his cancer journey offers an opportunity to examine what has changed in the treatment of advanced prostate cancer — and the hope these offer men living with the disease.I recently saw a patient who was diagnosed three years ago with cancer that had already spread to multiple areas in his bones. Since then, he has taken cruises, traveled with his family and spent weekends babysitting his grandchildren.He gets tired and cannot garden the way he once did. But he is still alive and considers every day a blessing. His experience, and what we see with Biden, shows what living with metastatic prostate cancer can look like today.Understanding survival ratesIf they haven’t asked their doctor already, many patients go online and find five-year survival rates, but every number they may find online comes with a huge asterisk.The American Cancer Society reports five-year relative survival of greater than 99% when prostate cancer is found in or near the prostate. The figure drops to 38% when it has reached distant parts of the body.But that number is based on large groups of men treated years ago. It does not fully reflect the impact of newer treatments — or account for an individual man’s age, overall health and response to therapy.Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live. These patients’ outlook depends on details of their cancer and how they are responding to treatments.It’s treated more aggressively nowA man diagnosed with metastatic prostate cancer a decade ago and a man diagnosed today would not receive the same treatment. The thinking now is to use our best treatments early instead of holding back.For years, doctors began with hormone therapy — usually injections that lower testosterone — and saved other treatments until the cancer stopped responding.Today, those injections are often combined from the start with a newer hormone-blocking drug and/or chemotherapy. These combinations have helped men live longer and are one of the biggest shifts of the past decade.What Biden’s diagnosis told usThere are three details about Biden’s cancer that help doctors like me understand how aggressive it is and how to manage it effectively. Official statements highlighted that his cancer had a Gleason score of 9. The cancer had spread to his bones, and it was labeled as hormone-sensitive.The Gleason score is assigned after a pathologist examines biopsy samples. Scores typically range from 6 to 10, with higher numbers indicating more aggressive cancer. A score of 9 falls into the most aggressive category. However, the score alone cannot tell us whether the cancer has spread outside the prostate.When prostate cancer spreads, the most common destination is the bones — particularly the spine, pelvis and ribs. It can also reach organs such as the lungs or liver. Once it has reached distant parts of the body, it is generally not curable, but treatment can put a brake on it for years.Prostate cancer can also be hormone-sensitive or hormone-resistant. Because it typically relies on testosterone to grow, lowering the hormone or blocking its effects can help control the cancer. Hormone-sensitive means it still responds to these treatments.Over time, most advanced or metastatic prostate cancers find ways to grow despite low testosterone levels, which mean they are now hormone-resistant. Lowering testosterone alone is no longer enough to control the cancer, so doctors have to turn to additional therapies.Knowing if the cancer has spreadThe most sensitive imaging test available today is a PSMA PET scan. It uses a radioactive tracer that seeks out a protein found on the surface of prostate cancer cells. Areas containing cancer may appear as bright spots, helping identify where the cancer has spread. The American Urological Association supports using this imaging test to determine whether high-risk prostate cancer has spread and to help establish its stage.A traditional bone scan, used for decades, highlights areas where bone is reacting to injury or disease. It remains an alternative imaging option, but PSMA PET is increasingly replacing its use.What areas light up and where matter when deciding on treatments. A single spot in the spine and cancer that has spread to the liver are both called stage 4, but they are not the same disease and may not be treated the same way.Doctors also consider how much cancer has spread. We label it as “low-volume” disease when the cancer has reached a limited number of areas. High volume is when the spread is more widespread or has reached other organs such as the liver or lungs.Both require treatment that works throughout the body. Treatment for metastatic disease generally includes therapy that works throughout the body. For men with low-volume disease, adding radiation to the prostate may also help them live longer.Biden has completed a course of radiation, but his team has not disclosed what area was treated or enough detail to determine whether his cancer would be considered low- or high-volume.Treatment has become more preciseBeyond starting more treatments earlier, doctors can increasingly tailor therapy to the biology of an individual man’s cancer. We can now test both the tumor and a patient’s own DNA for mutations that help guide treatment.Roughly 1 in 10 men with metastatic prostate cancer carries an inherited mutation affecting the body’s ability to repair DNA. The best known are BRCA1 and BRCA2, the same genes linked to some breast and ovarian cancers.Certain mutations found in the tumor or inherited DNA may make targeted drugs called PARP inhibitors an option. If a mutation is inherited, it also gives family members information they can act on through genetic counseling, testing and earlier screening.Another advance is radioligand therapy. If a scan shows that cancer cells carry a protein called PSMA, doctors can attach radiation to a molecule that seeks out that protein. Delivered through an IV, it targets cancer cells throughout the body. This approach was expanded last year to more men whose cancer had become hormone resistant.Living longer can come with costsEvery treatment can cause side effects. With hormone therapy, one of the first is often hot flashes, similar to what women experience during menopause. These are not dangerous, but they can affect a man’s quality of life.Fatigue is also common. Testosterone helps maintain muscle, so lowering it can reduce strength and energy. Regular walking and resistance training can help preserve muscle and reduce fatigue.The side effect almost no one talks about is loss of sex drive or low libido. At diagnosis, most men are thinking about staying alive, not their libido. But months later, it often matters. It is worth discussing with your care team and your partner rather than assuming it is simply the price of treatment.The side effect I worry about most is weaker bones. Low testosterone reduces bone density, while cancer deposits can weaken the bone’s structure. Follow-up care should include exercise, a bone-density scan, and ensuring adequate levels of calcium and vitamin D. For men with hormone-resistant cancer that has spread to bone, bone-protecting drugs can reduce the risk of fractures and other complications.New or worsening back pain, especially with leg weakness, numbness or trouble controlling the bladder or bowels? These could mean the cancer is pressing on the spinal cord. It is a true medical emergency that requires immediate attention.Cancer care requires a team approachIdeally, several doctors work together to coordinate a patient’s care. The urologist is often the starting point. A medical oncologist manages treatments that work throughout the body, while a radiation oncologist targets specific areas, whether that is the prostate itself or a painful bone lesion. The primary care doctor helps protect the patient’s heart and bones and looks after the person’s overall health.A man’s age, other medical conditions, ability to tolerate side effects and goals for treatment all shape treatment plans. Two men with nearly identical test results may be offered — or choose — different paths based on their health and priorities.Good communication among doctors is essential, but gaps can happen. Being your own advocate means knowing who is on your care team, asking questions and understanding your options.I also recommend bringing someone you trust to important visits for support and to take notes and help you remember what was discussed.More treatments, better testing offer hopeFor men worried about prostate cancer, talk with your health care provider about the benefits and risks of PSA testing. Black men and those with a strong family history should begin that conversation in their 40s. New urinary symptoms are often not cancer, but they still deserve attention, as does blood in the urine or semen, unexplained weight loss and/or persistent back or bone pain.For men living with advanced prostate cancer, there is reason for hope. There are more treatments and better testing than there were a decade ago, and good care pays attention to how a man feels, not just to what his scans show.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story